Raymond James Financial
RIGL icon

Raymond James Financial’s Rigel Pharmaceuticals RIGL Stock Holding History

Raymond James Financial’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.6M Buy
40,820
+2,687
+7% +$82.9K ﹤0.01% 3670
2026
Q1 		$1.03M Sell
38,133
-5,622
-13% -$189K ﹤0.01% 3827
2025
Q4 		$1.87M Buy
43,755
+236
+0.5% +$8.9K ﹤0.01% 3324
2025
Q3 		$1.23M Buy
43,519
+43,419
+43,419% +$1.3M ﹤0.01% 3545
2025
Q2 		$1.87K Buy
+100
New +$1.9K ﹤0.01% 6432

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's RIGL Position: Q2 2026 in Review

Raymond James Financial increased its Rigel Pharmaceuticals (RIGL) stake by 7% in Q2 2026, buying an estimated $82.9K and bringing the position to 40,820 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3670.

Raymond James Financial first reported a position in RIGL in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.87M in Q4 2025. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Raymond James Financial held 40,820 shares of Rigel Pharmaceuticals worth $1.6M as of Q2 2026.
  • Raymond James Financial bought 2,687 Rigel Pharmaceuticals shares in Q2 2026, an estimated $82.9K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3670 holding.
  • Raymond James Financial first reported a position in Rigel Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Raymond James Financial's Rigel Pharmaceuticals position peaked at $1.87M in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.